US 11,052,172 B2
Hemostatic flowable
William Spotnitz, Gainesville, FL (US); Valérie Centis, Lyons (FR); Doris Moura Campos, Bourgoin Jallieu (FR); and Alexia De Gasperis, Saint Genis Laval (FR)
Assigned to BIOM'UP FRANCE SAS, Saint-Priest (FR)
Appl. No. 16/324,637
Filed by BIOM'UP, Saint-Priest (FR)
PCT Filed Aug. 11, 2017, PCT No. PCT/EP2017/070428
§ 371(c)(1), (2) Date Feb. 11, 2019,
PCT Pub. No. WO2018/029340, PCT Pub. Date Feb. 15, 2018.
Claims priority of application No. 16184119 (EP), filed on Aug. 12, 2016.
Prior Publication US 2019/0167840 A1, Jun. 6, 2019
Int. Cl. A61L 26/00 (2006.01)
CPC A61L 26/0052 (2013.01) [A61L 26/008 (2013.01); A61L 26/0066 (2013.01); A61L 2300/232 (2013.01); A61L 2300/236 (2013.01); A61L 2300/252 (2013.01); A61L 2300/418 (2013.01); A61L 2400/04 (2013.01); A61L 2400/06 (2013.01)] 30 Claims
1. A kit to prepare an hemostatic flowable comprising:
a hemostatic powder having a composition comprising:
non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen;
at least one monosaccharide; and
at least one glycosaminoglycan;
a component which makes the hemostatic flowable, wherein said component consists of a saline solution to be mixed with the hemostatic powder.